Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Central Serous Chorioretinopathy: early-phase trial registry
1 of 6 indexed Central Serous Chorioretinopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Central Serous Chorioretinopathy: 6 US clinical trials tracked, 1 recruiting.
Central Serous Chorioretinopathy is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Wills Eye, running 2 of these trials.
Enrollment posture brief
Registry condition central-serous-chorioretinopathy
OPEN 1 | RECR 17% | LATE 0 | EARLY 3 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Central Serous Chorioretinopathy lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Central Serous Chorioretinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Central Serous Chorioretinopathy is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Central Serous Chorioretinopathy research.
Wills Eye accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Central Serous Chorioretinopathy enrolment sits around 108 participants.
Median target enrolment is 108 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Central Serous Chorioretinopathy splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
OCT in Rare Chorioretinal Diseases
Oregon Health and Science University
NCT02141308
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
Sequenom
NCT01880788
Eplerenone for the Treatment of Central Serous Chorioretinopathy
Wills Eye
NCT01990677
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Roger Goldberg, M.D., MBA
NCT02354170
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Wills Eye
NCT01710332
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Vitreous -Retina- Macula Consultants of New York
NCT00403325
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Central Serous Chorioretinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Central Serous Chorioretinopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Central Serous Chorioretinopathy page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Central Serous Chorioretinopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Wills Eye sponsors the most Central Serous Chorioretinopathy trials on record, review their full trial history before evaluating a specific study. See Wills Eye's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Central Serous Chorioretinopathy condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.